Investors Hangout Stock Message Boards Logo
  • Mailbox
  • Favorites
  • Boards
    • The Hangout
    • NASDAQ
    • NYSE
    • OTC Markets
    • All Boards
  • Whats Hot!
    • Recent Activity
    • Most Viewed Boards
    • Most Viewed Posts
    • Most Posted
    • Most Followed
    • Top Boards
    • Newest Boards
    • Newest Members
  • Blog
    • Recent Blog Posts
    • Recently Updated
    • News
    • Stocks
    • Crypto
    • Investing
    • Business
    • Markets
    • Economy
    • Real Estate
    • Personal Finance
  • Market Movers
  • Interactive Charts
  • Login - Join Now FREE!
  1. Home ›
  2. Stock Message Boards ›
  3. User Boards ›
  4. NASDAQ OMX GlobeNewswire Message Board

Global $8.9 Billion Actinic Keratosis Market 2012-

Message Board Public Reply | Private Reply | Keep | Replies (0)                   Post New Msg
Edit Msg () | Previous | Next


Post# of 301275
(Total Views: 30)
Posted On: 02/27/2017 4:30:25 AM
Avatar
Posted By: News Desk 2018
Global $8.9 Billion Actinic Keratosis Market 2012-2016 & Forecasts to 2022: High Prevalence Of Actinic Keratosis And Subsequent Risk Of Developing Malignancies Drives the Market

Dublin, Feb. 27, 2017 (GLOBE NEWSWIRE) -- Research and Markets has announced the addition of the "Global Actinic Keratosis Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2012 To 2022" report to their offering. Actinic keratosis (AK) is portrayed by skin papules, macules or plaques coming about because of delayed presentation to hurtful UV introduction and can bring about squamous cell carcinoma. Danger of creating actinic keratosis increments with propelling age and is especially higher in men as against ladies. Around 5-20% of patients with actinic keratosis injuries create dangerous and conceivably deadly squamous cell carcinomas. Among the different treatment strategies accessible, ruinous treatments, for example, fluid nitrogen cryotherapy and surgical treatment constitute the highest quality level for AK treatment. In 2015, cryotherapy was the most ordinarily looked for treatment by clinicians. Notwithstanding, better clinical consequences of photodynamic treatment and developing inclination for medications in view of medication gadget mix have asked both parental figures and patients to choose novel treatment techniques that offer both propelled adequacy, stylish advantages and decreased danger of future malignancies. North America is the biggest market for actinic keratosis treatment because of developing predominance of AK, better open mindfulness about event of AK and related danger of squamous cell carcinoma. As per American Academy of Dermatology (AAD), around 60% of the Americans matured 40 year or above, Actinic Keratosis is inclined to create having no less than 1 AK injury. Actinic keratosis is antecedents of squamous cell disease. U.S. held the biggest partake in the actinic keratosis market in 2015 attributable to current commonness of actinic keratosis in the region. Asia Pacific is the quickest developing market for AK medicines. Australia has the most astounding pervasiveness of actinic keratosis going between 40% to 60% in grown-up populace. Developing mindfulness in the area and fast improvement in social insurance framework and human services use are the key development figures Asia Pacific actinic keratosis market. This market is significantly determined by wide nearness of bland medications and is modestly aggressive. Photodynamic treatment market has built up a specialty with methyl aminolevulinate and aminolevulinic corrosive medications. Galderma and DUSA pharmaceuticals are the main players in this space. A portion of the real players in the worldwide actinic keratosis market are Tolmar Pharmaceuticals, Inc, DUSA Pharmaceuticals, Inc., Valeant Pharmaceuticals International, Inc., Aqua Pharmaceuticals, LLC, Galderma SA, Perrigo Company plc, LEO Laboratories, Apotex and others. Key Topics Covered: Chapter 1 Preface 1.1 Report Description 1.1.1 Purpose Of The Report 1.1.2 Target Audience 1.1.3 Usp And Key Offerings 1.2 Research Scope 1.3 Research Methodology 1.3.4 Assumptions Chapter 2 Executive Summary 2.1 Global Actinic Keratosis Market Revenue, By Treatment, 2015, (Us$ Mn) 2.2 Global Actinic Keratosis Market Revenue, By Geography, 2015, (USD Million) Chapter 3 Market Overview 3.1 Introduction And Market Definition 3.2 Market Inclination Insights 3.3 Market Dynamics 3.3.1 Drivers 3.3.1.1 High Prevalence Of Actinic Keratosis And Subsequent Risk Of Developing Malignancies 3.3.2 Restraints 3.3.2.1 Non-Adherence To Treatments 3.3.3 Market Opportunities 3.3.3.1 Lucrative Future For Light-Based Treatments 3.4 Attractive Investment Proposition 3.5 Market Competition Assessment Key Players: Global Actinic Keratosis Market Chapter 4 Global Actinic Keratosis Market, By Treatments 4.1 Preface 4.2 Destructive Treatment 4.2.1 Liquid Nitrogen Cryotherapy 4.2.2 Surgical Therapy 4.3 Photodynamic Therapy 4.3.1 5-Aminolevulinic Acid (Ala) 4.3.2 Methyl Aminolevulinate (Mal) 4.4 Topical Medications 4.4.1 5-Fluorouracil [5-Fu] 4.4.2 Imiquimod 4.4.3 Ingenol Mebutate 4.4.4 Diclofenac Sodium 4.5 Chemical Peels And Dermabrasion Chapter 5 Global Actinic Keratosis Market, By Geography Chapter 6 Company Profiles

  • Apotex, Inc.
  • Aqua Pharmaceuticals, Llc
  • Dusa Pharmaceuticals, Inc. (Sun Pharma)
  • Galderma S.A.
  • Leo Laboratories Ltd. (Leo Pharma A/S)
  • Perrigo Company Plc,
  • Tolmar Pharmaceuticals, Inc.
  • Valeant Pharmaceuticals International, Inc.

For more information about this report visit http://www.researchandmarkets.com/research/tn...al_actinic

CONTACT: Research and Markets Laura Wood, Senior Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716 Related Topics: Skin Cancer Drugs



(0)
(0)








Investors Hangout

Home

Mailbox

Message Boards

Favorites

Whats Hot

Blog

Settings

Privacy Policy

Terms and Conditions

Disclaimer

Contact Us

Whats Hot

Recent Activity

Most Viewed Boards

Most Viewed Posts

Most Posted Boards

Most Followed

Top Boards

Newest Boards

Newest Members

Investors Hangout Message Boards

Welcome To Investors Hangout

Stock Message Boards

American Stock Exchange (AMEX)

NASDAQ Stock Exchange (NASDAQ)

New York Stock Exchange (NYSE)

Penny Stocks - (OTC)

User Boards

The Hangout

Private

Global Markets

Australian Securities Exchange (ASX)

Euronext Amsterdam (AMS)

Euronext Brussels (BRU)

Euronext Lisbon (LIS)

Euronext Paris (PAR)

Foreign Exchange (FOREX)

Hong Kong Stock Exchange (HKEX)

London Stock Exchange (LSE)

Milan Stock Exchange (MLSE)

New Zealand Exchange (NZX)

Singapore Stock Exchange (SGX)

Toronto Stock Exchange (TSX)

Contact Investors Hangout

Email Us

Follow Investors Hangout

Twitter

YouTube

Facebook

Market Data powered by QuoteMedia. Copyright © 2025. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges).
Analyst Ratings & Earnings by Zacks. RT=Real-Time, EOD=End of Day, PD=Previous Day. Terms of Use.

© 2025 Copyright Investors Hangout, LLC All Rights Reserved.

Privacy Policy |Do Not Sell My Information | Terms & Conditions | Disclaimer | Help | Contact Us